Aspects of Peptidomimetics - Peptide and Protein Design for Biopharmaceutical Applications - page 126

[318] A. Volonterio, L. Moisan and J. Julius, Synthesis of pyridazine-based scaffolds as
alpha-helix mimetics, Org.Lett ., 9, 3733-3736 (2007).
[319] L. Moisan, S. Odermatt, N. Gombosuren, A. Carella and J. Rebek, Synthesis of an
oxazole-pyrrole-piperazine scaffold as an alpha-helix mimetic, Eur. J. Org. Chem .,
10, 1673-1676 (2008).
[320] P. Maity and B. Konig, Synthesis and structure of 1,4-dipiperazino benzenes: Chiral
terphenyl-type peptide helix mimetics, Org.Lett ., 10, 1473-1476 (2008).
[321] Y. Che, B. R. Brooks and G. R. Marshall, Protein recognition motifs: Design of
peptidomimetics of helix surfaces, Biopolymers , 86, 288-297 (2007).
[322] W. Antuch, S. Menon, Q. Z. Chen, Y. C. Lu, S. Sakamuri, B. Beck, V. Schauer-
Vukasinovic, S. Agarwal, S. Hess and A. Domling, Design and modular parallel
synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhi-
bitor scaffold, Bioorg.Med.Chem.Lett ., 16, 1740-1743 (2006).
[323] H. Oguri, A. Oomura, S. Tanabe and M. Hirama, Design and synthesis of a trans -
fused polycyclic ether skeleton as an a-helix mimetic scaffold, Tetrahedron Lett .,
46, 2179-2183 (2005).
[324] H. Oguri, S. Tanabe, A. Oomura, M. Umetsu and M. Hirama, Synthesis and
evaluation of a-helix mimetics based on a trans-fused polycyclic ether: sequence-
selective binding to aspartate pairs in a-helical peptides, Tetrahedron Lett ., 47,
5801-5805 (2006).
[325] S. E. Van Compernolle, A. V. Wiznycia, J. R. Rush, M. Dhanasekaran, P. W. Baures
and S. C. Todd, Small molecule inhibition of hepatitis C virus E2 binding to CD81,
Virology , 314, 371-380 (2003).
[326] A. L. Rodriguez, A. Tamrazi, M. L. Collins and J. A. Katzenellenbogen, Design,
synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen
receptor a coactivator binding, J.Med.Chem ., 47, 600-611 (2004).
[327] J. S. Blakeney, R. C. Reid, G. T. Le and D. P. Fairlie, Nonpeptidic ligands for peptide-
activated G protein-coupled receptors, Chem.Rev ., 107, 2960-3041 (2007).
[328] N. R. A. Beeley, Can peptides be mimicked?, Drug Discov.Today , 5, 354-363 (2000).
[329] R. M. Jones, P. D. Boatman, G. Semple, Y.-J. Shin and S. Y. Tamura, Clinically
validated peptides as template for de novo peptidomimetic drug design at G-protein-
coupled receptors, Curr.Opin.Pharmacol ., 3, 530-543 (2003).
[330] A. Janecka, M. Zubrzycka and T. Janecki, Somatostatin analogues, J. Peptide Res. ,
58, 91-107 (2001).
[331] L. Yang, Non-peptide Somatostatin Receptor Ligands, In: Annu. Rep. Med. Chem .,
1999, ch. 21, 209-218.
[332] R. M. Freidinger, Design and synthesis of novel bioactive peptides and peptidomim-
eties, J.Med.Chem ., 46, 5553-5566 (2003).
[333] R. H. Mattern, S. B. Moore, T. A. Tran, J. K. Rueter and M. Goodman, Synthesis,
biological activities and conformational studies of somatostatin analogues,

Tetrahedron , 56, 9819-9831 (2000).
[334] V. Prasad, E. T. Birzin, C. T. McVaugh, R. D. van Rijn, S. P. Rohrer, G. Chicchi,
D. J. Underwood, E. R. Thornton, A. B. Smith and R. Hirschmann, Effects of
heterocyclic aromatic substituents on binding affinities at two distinct sites of
somatostatin receptors. Correlation with the electrostatic potential of the substitu-
ents, J.Med.Chem ., 46, 1858-1869 (2003).
[335] R. Hirschmann, K. C. Nicolaou, S. Pietranico, J. Salvino, E. M. Leahy,

P. A. Sprengeler, G. Furst, A. B. Smith, C. D. Strader, M. A. Cascieri,